NEW YORK (GenomeWeb News) – Investment bank Goldman Sachs today upgraded shares of Quest Diagnostics and Laboratory Corporation of America, but downgraded Sigma-Aldrich.

In a research note, analyst Isaac Ro upgraded Quest to Buy from Neutral and LabCorp to Neutral from Sell. He downgraded Sigma-Aldrich to Sell from Neutral.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.